Outcome of urethral strictures treated by endoscopic urethrotomy and urethroplasty.

INTRODUCTION: We analyze the outcomes of patients with urethral stricture who underwent surgical treatment within the past 5 years. METHODS: This is a retrospective study of male patients who underwent surgery for urethral stricture at our service from January 2008 to June 2012. We analyzed the comorbidities, type, length and location of the stricture and the surgical treatment outcome after endoscopic urethrotomy, urethroplasty or both. RESULTS: In total, 45 patients with a mean age of 53.7 ± 16.7 years underwent surgical treatment for urethral stricture. Six months after surgery, 46.7% of the patients had a maximum urinary flow greater than 15 mL/s, whereas 87.3% of the patients exhibited no stricture by urethrography after the treatment. The success rate in the patients undergoing urethrotomy was 47.8% versus 86.4% in those undergoing urethroplasty (p = 0.01). Twenty percent of the patients in whom the initial urethrotomy had failed subsequently underwent urethroplasty, thereby increasing the treatment success. CONCLUSION: In most cases, the treatment of choice for urethral stricture should be urethroplasty. Previous treatment with urethrotomy does not appear to produce adverse effects that affect the outcome of a urethroplasty if urethrotomy failed, so urethrotomy may be indicated in patients with short strictures or in patients at high surgical risk.

Metabolic syndrome, hormone levels, and inflammation in patients with erectile dysfunction.

BACKGROUND: The end point of this study was to investigate the prevalence of MS in patients with ED in comparison with control subjects and to analyse the association with acute phase reactants (CRP, ESR) and hormone levels. METHODS: This case-control study included 65 patients, 37 with erectile dysfunction, according to the International Index of Erectile Function (IIEF) from the Urology Department of San Cecilio University Hospital, Granada (Spain) and 28 healthy controls. The prevalence of metabolic syndrome was calculated according to ATP-III criteria. Hormone levels and acute phase parameters were studied in samples drawn. RESULTS: The ATP-III criteria for MS were met by 64.9% of the patients with ED and only 9.5% of the controls (P < 0.0001, OR = 17.53, 95% CI: 3.52-87.37). Binary logistic regression analysis showed a strong association between patients with ED and MS, even after additional adjustment for confounding factors (OR = 20.05, 95% CI: 1.24-32.82, P < 0.034). Patients with hypogonadism presented a significantly higher prevalence of metabolic syndrome. Multiple linear regression analysis showed that systolic BP and CRP predicted 0.46 (model R²) of IIEF changes. CONCLUSION: Chronic inflammation found in patients with ED might explain the association between ED and metabolic syndrome.

Complications from the placement of a tension-free suburethral sling using the transobturator and retropubic methods for treatment of female urinary incontinence.

OBJECTIVE: The aim of our study was to retrospectively analyze surgical complications arising from the collocation of suburethral mesh in the lower urinary tract, using both the transobturator and retropubic methods. PATIENTS AND METHODS: During the period between November 2002 and June 2011, we retrospectively studied 190 patients that were treated for stress urinary incontinence using a tension-free suburethral sling. 50 patients were treated using the retropubic route (SPARC®), and 140 patients were treated using a transobturator (MONARC®). RESULTS: In total, 16.57% of the patients presented with intraoperative, immediate postoperative or later postoperative complications. We observed a higher rate of complications with patients who were operated on retropubically (26%) than with patients who were operated on using the transobturator method (12%). CONCLUSIONS: The rate of complications for our study was low, and was even lower in the case of transobturator tape. Thus, we usually used transobturator tape in the treatment of stress incontinence.

Randomized clinical trial on antimicrobial prophylaxis for flexible urethrocystoscopy.

OBJECTIVES: One of the main drawbacks of flexible urethrocystoscopy is the risk of urinary tract infection (UTI). In order to reduce this risk, antimicrobial prophylaxis has been considered, however there is not a unanimous view regarding indications, dosage, type of antibiotic, and so on. To clarify this uncertainty, we practiced a pilot and experimental study aimed at assessing the effectiveness of chemoprophylaxis with 3 grams of fosfomycin trometamol in the prevention of UTI after urethrocystoscopy. METHODS: Sixty patients were entered into a pilot randomized clinical trial between March and August 2011. Thirty patients were assigned to a control group without receiving any antibiotic dose, and the intervention group (30 patients) received 3 g fosfomycin trometamol. Ten days later urine culture and sediment analysis were performed in all patients. Significant bacteriuria was considered from > 105 CFU /ml. One month later a telephone survey was developed to assess urinary symptoms, and assistance to the family doctor. We estimated the cumulative incidence of bacteriuria, pyuria and microhematuria in both groups, and we compared the results using a strategy of analysis per protocol and intention to treat. RESULTS: The incidence of bacteriuria, pyuria and microhematuria in the control group was 10%, 23.3% and 26.7% respectively and in the intervention groups the values differed depending on the type of analysis. Considering only the 27 patients (per protocol analysis), the incidence would be 11.1%, 37.0% and 29.6% respectively. If we include the three patients who did not completed the study (per intention to treat analysis) and considering their results as negative, the results were 10%, 33.3% and 26.7% respectively. Finally, in the case the three cultures not performed in this group had produced a positive result, the impact would have been 20.0%, 43.3% and 36.7%. In any of the three cases, the differences with the control group were not statistically significant. CONCLUSIONS: In a selected population and with appropriate aseptic measures, antibiotic chemoprophylaxis does not appear to show a clinically relevant reduction in the incidence of UTI in patients undergoing flexible urethrocystoscopy.

Ensayo clínico aleatorizado sobre profilaxis antibiótica en la uretrocistoscopia flexible / Randomized clinical trial on antimicrobial prophylaxis for flexible urethrocystoscopy

OBJETIVO: Uno de los principales inconvenientes de la uretrocistoscopia flexible es el riesgo de infección del tracto urinario (ITU). Para intentar reducir dicho riesgo se ha recurrido a la profilaxis antimicrobiana, aunque aún no hay un criterio unánime en cuanto a la pertinencia de su indicación, dosis, vía de administración y tipo de antibiótico de la misma. Para clarificar esta incertidumbre, hemos planteado un estudio experimental con el objetivo de valorar la eficacia de la quimioprofilaxis con 3 g de fosfomicina trometamol en la prevención de la ITU post uretrocistoscopia. MÉTODOS: Sesenta pacientes fueron incluidos en un ensayo clínico randomizado entre Marzo y Agosto del 2011. Treinta pacientes fueron asignados a un grupo control, que no recibió ninguna dosis de antibiótico, y el grupo de intervención (30 pacientes) recibió 3 g de fosfomicina trometamol. Díez días más tarde se realizó a todos los pacientes un sedimento y cultivo de orina. La bacteriuria significativa fué considerada a partir de > 105 UFC/ml. Un mes más tarde se llevó a cabo una encuesta telefónica para recoger los síntomas urinarios y la asistencia a su médico de familia. Estimamos la incidencia acumulada de bacteriuria, piuria y microhematuria en ambos grupos, y comparamos los resultados usando una estrategia de análisis por protocolo y por intención de tratar(AU)

RESULTADOS: La incidencia de bacteriuria, piuria y microhematuria fué en el grupo control del 10%, 23.3% y 26.7% respectivamente y en el de intervención los valores difirieron dependiendo del tipo de análisis. Considerando solamente los 27 pacientes (análisis por protocolo), las incidencias serían del 11,1%, 37,0% y 29,6%, respectivamente. Si incluimos los tres pacientes que no finalizaron el estudio (análisis por intención de tratar) y consideramos sus resultados como negativos, los resultados serían del 10%, 33,3% y 26,7%, respectivamente. Finalmente, en el caso de que los tres cultivos no realizados en este grupo hubieran arrojado un resultado positivo, las incidencias habrían sido de 20,0%, 43,3% y 36,7%. En cualquiera de los tres supuestos, las diferencias con respecto al grupo control no son estadísticamente significativas. CONCLUSIONES: En una población seleccionada y con unas medidas de asepsia adecuadas, la quimioprofilaxis no parece mostrar una reducción clínicamente relevante en la incidencia de ITU en pacientes sometidos a uretrocistoscopia flexible(AU)

OBJECTIVES: One of the main drawbacks of flexible urethrocystoscopy is the risk of urinary tract infection (UTI). In order to reduce this risk, antimicrobial prophylaxis has been considered, however there is not a unanimous view regarding indications, dosage, type of antibiotic, and so on. To clarify this uncertainty, we practiced a pilot and experimental study aimed at assessing the effectiveness of chemoprophylaxis with 3 grams of fosfomycin trometamol in the prevention of UTI after urethrocystoscopy. METHODS: Sixty patients were entered into a pilot randomized clinical trial between March and August 2011. Thirty patients were assigned to a control group without receiving any antibiotic dose, and the intervention group (30 patients) received 3 g fosfomycin trometamol. Ten days later urine culture and sediment analysis were performed in all patients. Significant bacteriuria was considered from > 105 CFU /ml. One month later a telephone survey was developed to assess urinary symptoms, and assistance to the family doctor. We estimated the cumulative incidence of bacteriuria, pyuria and microhematuria in both groups, and we compared the results using a strategy of analysis per protocol and intention to treat(AU)

RESULTS: The incidence of bacteriuria, pyuria and microhematuria in the control group was 10%, 23.3% and 26.7% respectively and in the intervention groups the values differed depending on the type of analysis. Considering only the 27 patients (per protocol analysis), the incidence would be 11.1%, 37.0% and 29.6% respectively. If we include the three patients who did not completed the study (per intention to treat analysis) and considering their results as negative, the results were 10%, 33.3% and 26.7% respectively. Finally, in the case the three cultures not performed in this group had produced a positive result, the impact would have been 20.0%, 43.3% and 36.7%. In any of the three cases, the differences with the control group were not statistically significant. CONCLUSIONS: In a selected population and with appropriate aseptic measures, antibiotic chemoprophylaxis does not appear to show a clinically relevant reduction in the incidence of UTI in patients undergoing flexible urethrocystoscopy(AU)

Mineral density and bone remodelling markers in patients with calcium lithiasis.

UNLABELLED: What's known on the subject? and What does the study add? Hypercalciuria is related with bone mineral density loss. This study demonstrates the relationship between recurrent calcium nephrolithiasis and bone mineral density loss and their correlation with bone markers. OBJECTIVES: • To show that a relationship exists between the loss of bone mineral density (BMD) and calcium renal lithiasis and that bone remodelling markers correlate with changes in BMD. • It is possible that many cases hypercalciuria are related to the increase of bone turnover and the predominance of bone resorption phenomena. PATIENTS AND METHODS: • The present study comprised a transversal investigation in three groups: group O, without lithiasis; group A, with a single episode of lithiasis; and group B, with relapsed calcium renal lithiasis. • An analysis was made of body mass index; abdominal X-ray and/or urography and renal ultrasonography; osteocalcin and ß-crosslaps bone markers; calcium and citrate concentrations in the urine; and femur and spinal column bone densitometry. • The results were analyzed by analysis of variance and Pearson's correlation coefficient. RESULTS: • Patients with relapsed calcium renal lithiasis present a greater BMD loss than those in the O or A groups. • Densitometry: T-score femur -0.2 group O, -0.5 group A, -1.2 group B (P= 0.001); T-score column -0.6 group O, -0.6 group A, -1.3 group B (P= 0.05). • A statistically significant negative correlation exists between values of ß-crosslaps and T-score femur (R=-0.251; P= 0.009) and T-score column (R=-0.324; P= 0.001); thus, a higher concentration of ß-crosslaps was accompanied by a lower value of the T-score and a greater loss of BMD. • A positive relationship is observed between ß-crosslaps and osteocalcin (R= 0.611; P < 0.001) and between calciuria and cocient ß-crosslaps/osteocalcin (R= 0.303; P= 0.001). CONCLUSIONS: • A statistically significant relationship is shown between the loss of BMD and relapsed calcium renal lithiasis. • Determination of bone remodelling markers (i.e. osteocalcin and ß-crosslaps) facilitates the diagnosis of osteopaenia/osteoporosis in these patients.